dapagliflozin - Resultados de la búsqueda

Unión Europea - español - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Unión Europea - español - EMA (European Medicines Agency)

forxiga

astrazeneca ab - dapagliflozin propanediol monohidrato - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. además de otros productos medicinales para el tratamiento de la diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Unión Europea - español - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin propanediol monohidrato - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. además de otros productos medicinales para el tratamiento de la diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

forxiga 10mg comprimido recubierto

astrazeneca peru s.a. - droguerÍa - dapagliflozina; - comprimido recubierto - por comprimido - - dapagliflozina

Unión Europea - español - EMA (European Medicines Agency)

ebymect

astrazeneca ab - dapagliflozin propanodiol monohidrato, metformin hidrocloruro - diabetes mellitus, tipo 2 - drogas usadas en diabetes - la diabetes tipo 2 mellitusfor el tratamiento de la insuficientemente controlada la diabetes mellitus tipo 2 como un complemento a la dieta y el ejercicio. como monoterapia cuando la metformina se considera inadecuado debido a la intolerancia. además de otros productos medicinales para el tratamiento de la diabetes tipo 2. para que los resultados del estudio con respecto a la combinación de las terapias, los efectos sobre el control glucémico y los eventos cardiovasculares, y las poblaciones estudiadas, ver las secciones 4. 4, 4. 5 y 5. la diabetes tipo 1 mellitusedistride está indicado en adultos para el tratamiento de insuficientemente controlada la diabetes mellitus tipo 1 como un complemento a la insulina en pacientes con imc ≥ 27 kg/m2, cuando la insulina por sí solas no proporcionan un adecuado control de la glucemia a pesar de la terapia con insulina óptima.